Dr. Mouquet earned a BS in Biochemistry, a MS in Biochemistry & Molecular Biology and a PhD in Immunology from the University of Rouen (Normandy, France). He performed his post-doctoral trainee in the laboratory of Michel C. Nussenzweig at the Rockefeller University (2007-2013), where he studied B-cell antibody response to HIV-1, isolated and characterized HIV-1 bNAbs. In 2013, Hugo started his group as a young investigator in the immunology department of the Institut Pasteur, supported by an ERC starting grant award. He currently heads the laboratory of Humoral Immunology at the Institut Pasteur. His lab investigates the humoral responses to pathogens in humans with a focus on HIV-1, Hepatitis viruses and emerging infections, and a dual interest in basic and translational research.
Archive of the Group for AIDS Research
This page contains the list of past meetings held by the Group for AIDS Research (Groupe de Réflexion SIDA) of the Pasteur Institute since 2014. The list of previous meetings held since 2002 can […]
Group for AIDS Research
The Group for AIDS Research (Groupe de Réflexion SIDA, GRS) organizes bimonthly meetings and seminars around an HIV / AIDS research topic. Meetings and seminars are open to all. Meetings are usually held on […]
Influence of ART Timing on Mucosal B-cell Responses in HIV-1 Infected Individuals
This project in collaboration with Dr Sophie Huë (Service d’Immunologie Biologique, Hôpital Henri Mondor), and funded by Sidaction aims at understanding whether the timing of the antiretroviral therapy (ART) for AIDS treatment can positively influence B-cell / antibody responses […]
Clonal B cells in Cryoglobulinemia Vasculitis with Hepatitits C Infection
Hepatitis C virus (HCV) infection can trigger the development of autoimmune disorders among which, cryobulininemic vasculatitis is the most prevalent. HCV-associated cryobulininemic vasculatitis is mediated by mono-/oligo-clonal IgM cryoglobulins with rheumatoid factor activity, […]
Antiviral Properties of Broadly Neutralizing HIV-1 Antibodies
Broadly neutralizing HIV-1 antibodies (bNAbs) can develop in rare infected individuals several years after co-evolution with diversifying viruses. In animal models, passive immunotherapy with potent HIV-1 bNAbs has been shown to protect from infection […]
Human Antibody Responses to Viruses Adaptive immune responses naturally occurring upon infection or induced by vaccination generate high affinity antibodies, and memory B-cell subsets to respond to further antigenic challenges, providing protection against (re-)infections. […]
Methodological Approaches for Rapid Antibody Discovery
Capture of Single Antigen-Specific B cells to Produce Human Monoclonal Antibodies to Pathogens To achieve our research goals, we are making use of a very efficient method to clone and express immunoglobulins from human […]
2020Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models., Cell Host Microbe 2020 Dec; (): .
2020Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models, Cell Host and Microbe. 2020 Dec.
2020TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice., PLoS Pathog 2020 Nov; 16(11): e1009025.
2020Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier., mBio 2020 Oct; 11(5): .
2020Syncytia formation by SARS-CoV-2 infected cells., EMBO J 2020 Oct; (): e106267.
2020A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations., Sci Transl Med 2020 09; 12(559): .
2020Binding mechanisms of therapeutic antibodies to human CD20., Science 2020 Aug; 369(6505): 793-799.
2020Easy pan-detection of human IgA immunoglobulins., J. Immunol. Methods 2020 Aug; (): 112833.
2020Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3., EBioMedicine 2020 Jun; 57(): 102842.
2020Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers., J. Exp. Med. 2020 ; 217(10): .
+View full list of publications